Brought to you by 
Neurotech and NsGene swap technology
11 Oct 2000
Executive Summary
Two gene and cell therapy biotechs, Neurotech and NsGene, signed a cross-licensing agreement--NsGene gets rights to Neurotech's encapsulated cell technology (ECT) to develop treatments for epilepsy and neurodegenerative disorders, and Neurotech gets rights to NsGene's neurotrophic factor neublastin for ophthalmic indications.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neurotech and NsGene swap technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice